Skip to content
Trial Agents

Acm Medical Laboratory

Acm Medical Laboratory is recorded as a service provider in 38 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

38distinct trials
12recorded service labels
2trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 20 of 38 trials · Latest update first

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Sponsor Grin Therapeutics Inc.

Start (EU)
Latest update
Estimated end

A Phase 2a, proof-of-concept, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy and safety of ACT-777991 in adults with non-segmental vitiligo.

Sponsor Idorsia Pharmaceuticals Ltd.

Start (EU)
Latest update
Estimated end

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Sponsor River 3 Renal Corp.

Start (EU)
Latest update
Estimated end
Operational learnings available4 trial-level findings · Read insights
  • Of 96 screened patients, 53 screen failed.
  • Twenty-six centers in six countries consented at least one participant, but only 17 centers enrolled at least one participant.
  • Eligibility criteria were amended to lower the minimum eGFR from 45 to 30 mL/min/1.73 m² in both cohorts and the FSGS minimum UPCR from 3.5 to 1.5 g/g.
  • Intended 24-hour urine collections were added at baseline and end of treatment because of high variability in first-morning-void UPCR measurements.

These findings describe the trial, not the service provider’s performance or responsibility.

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Sponsor Elevara Medicines Limited

Start (EU)
Not reported
Latest update
Estimated end

A Phase 2a, Randomized, Placebo-Controlled, Double Blind Multiple Ascending Dose Study in Patients with Cystic Fibrosis Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84‎

Sponsor Splisense Ltd.

Start (EU)
Latest update
Estimated end

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis

Sponsor Priovant Therapeutics Inc.

Start (EU)
Latest update
Estimated end

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Sponsor Bial R&D Investments S.A.

Start (EU)
Latest update
Estimated end
Operational learnings available3 trial-level findings · Read insights
  • The study screened and enrolled 1,048 participants in genetic-screening Part A versus an estimate of up to 3,750 needed to randomize approximately 237 participants, and randomized 272 participants.
  • The trial operated at 86 sites across 11 countries, including 44 sites in nine European countries.
  • Among randomized participants, 230 (84.6%) completed dosing, and treatment exposure and compliance were high, comparable between groups, and stable throughout the study.

These findings describe the trial, not the service provider’s performance or responsibility.

Questions about this trial experience

What services are recorded for Acm Medical Laboratory?

The 2026-10-09 snapshot links Acm Medical Laboratory to 38 distinct CTIS trials. Recorded services include Laboratory services, Storage, Clinical chemistry, Clinical haematology, Serology/ endocrinology, Bioanalysis & Biomarker Services, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Acm Medical Laboratory?

The most frequently recorded therapeutic areas are Neurology, Immunology, Dermatology, Genetic and Congenital Disorders. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Acm Medical Laboratory conducted?

The linked trials record locations in 19 countries, including Spain, Poland, Germany, Italy, France. These are trial locations, not confirmed office locations or countries where Acm Medical Laboratory delivered services.

What can this page tell me about Acm Medical Laboratory's trial experience?

Browse 38 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Acm Medical Laboratory. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Acm Medical Laboratory Inc.

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.